SecBot SecBot
PRESS-RELEASE ·Filed Aug 11, 2026

NRXS

NeurAxis, Inc.
MIXED
Impact 5/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Monitor for additional commercial payer coverage decisions in H2 2026/early 2027, which are critical for sustained revenue growth. The shelf registration (S-3/A) poses dilution risk; watch for any takedown announcements.

DirectionMixed
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
NRXS ▼ -9.76% at T+20d
NEUTRAL call -9.76% · α vs SPY -8.70% · entry $6.35 → $5.73
Next anchor: T+60d in 8d
Latest observation: T+52 +53.40% FF3 residual α
Entry = T+0 close
Aug 11, 2026
via day close
T+1d
-1.26%
call -1.26% · α -1.51%
$6.27
settled 3mo ago
T+5d
-1.42%
call -1.42% · α -1.01%
$6.26
settled 2mo ago
T+20d
-9.76%
call -9.76% · α -8.70%
$5.73
settled 7w ago
T+60d
Pending
in 8d

Price Chart

Loading chart...

Executive Summary

NeurAxis reported Q2 2026 revenue of $1.9M (+116% YoY) and EPS of -$0.19 (40.6% beat vs -$0.32 consensus), driven by the new Category I CPT code for PENFS. However, net loss widened 23% to $2.09M, and the company's recent S-3/A shelf registration includes a going-concern reference, tempering the growth story with dilution and financial risk.

Key Financial Metrics

EPS
−$0.19
est −$0.32 · +40.6%
Revenue
$1.9M
est $2.0M · -3.6% · +115.7% YoY
Rating
in line
Gross Margin
85.9%

Key Facts

  • Revenue $1.93M vs $2.0M consensus (miss of ~3.6%)
  • EPS -$0.19 vs -$0.32 consensus (40.6% beat)
  • Revenue grew 116% YoY from $894K
  • Gross margin expanded 230 bps to 85.9%
  • Net loss increased 23% to $2.09M
  • Cash balance $8.3M; operating cash burn improved to $1.0M from $1.5M
  • S-3/A shelf registration filed 12 days ago with going-concern reference
  • Category I CPT code for PENFS effective Jan 2026 driving revenue growth

Financial Impact

Revenue growth of 116% YoY is strong, but net loss widening and shelf registration overhang create uncertainty.

revenuegross marginnet losscash burn

Risk Factors

  • Potential dilution from the shelf registration
  • Going-concern risk flagged in auditor's report
  • Increasing operating losses despite revenue growth
  • Dependence on payer coverage expansion for adoption

Market Snapshot

Exchange
NYSE
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3342584
14 reports for NRXS
Performance horizon
50% Hit rate @ T+20 2 of 4 directional calls Went positive at some point 3 of 4 best @ T+20▲ +17.12%Aug 4, 2026
Filters
Rows
Reports for NRXS — sortable, filterable
TypeNow
Oct 14, 2026
13d ago
8-K
NEUTRAL ★ 2/10
$7.74awaiting T+20—$7.36 (−4.91%)
Aug 19, 2026
9w ago
8-K
NEUTRAL ★ 2/10
$6.27 $7.61▲ +21.37%▲ +21.37%$7.36 (+17.38%)
Aug 11, 2026
11w ago
Press Release
MIXED ★ 5/10
$6.35 $5.73▼ −9.76%▼ −8.70%$7.36 (+15.91%)
Aug 4, 2026
12w ago
EFFECT
BEARISH ★ 6/10
$7.01 $5.81▲ +17.12%▲ +15.88%$7.36 (−4.99%)
Jul 30, 2026
12w ago
S-3/A
BEARISH ★ 6/10
$6.28 $6.02▲ +4.14%▲ +8.11%$7.36 (−17.20%)
Jul 10, 2026
15w ago
8-K
NEUTRAL ★ 2/10
$7.14 $7.09▼ −0.70%▼ −3.13%$7.36 (+3.08%)
May 12, 2026
24w ago
Press Release
BULLISH ★ 7/10
$8.27 $6.80▼ −17.78%▼ −16.05%$7.36 (−11.00%)
May 5, 2026
25w ago
Press Release
NEUTRAL ★ 1/10
$8.69 $7.01▼ −19.33%▼ −24.29%$7.36 (−15.30%)
Apr 28, 2026
26w ago
DEFA14A
NEUTRAL ★ 4/10
$7.44 $7.29▼ −2.02%▼ −8.06%$7.36 (−1.08%)
Apr 21, 2026
27w ago
8-K
BULLISH ★ 7/10
$7.51 $7.25▼ −3.46%▼ −6.63%$7.36 (−2.00%)
Showing 10 of 14

US Market Status

Market Closed — Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026